<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xml:lang="en" article-type="letter" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Clin Mol Hepatol</journal-id><journal-id journal-id-type="iso-abbrev">Clin Mol Hepatol</journal-id><journal-id journal-id-type="pmc-domain-id">1864</journal-id><journal-id journal-id-type="pmc-domain">cmh</journal-id><journal-id journal-id-type="publisher-id">CMH</journal-id><journal-title-group><journal-title>Clinical and Molecular Hepatology</journal-title></journal-title-group><issn pub-type="ppub">2287-2728</issn><issn pub-type="epub">2287-285X</issn><publisher><publisher-name>Korean Association for the Study of the Liver</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC12016607</article-id><article-id pub-id-type="pmcid-ver">PMC12016607.1</article-id><article-id pub-id-type="pmcaid">12016607</article-id><article-id pub-id-type="pmcaiid">12016607</article-id><article-id pub-id-type="pmid">39957370</article-id><article-id pub-id-type="doi">10.3350/cmh.2025.0166</article-id><article-id pub-id-type="publisher-id">cmh-2025-0166</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Correspondence</subject></subj-group></article-categories><title-group><article-title>Correspondence to editorial on &#8220;Global epidemiology of alcohol-related liver disease, liver cancer, and alcohol use disorder, 2000-2021&#8221;</article-title></title-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Danpanichkul</surname><given-names initials="P">Pojsakorn</given-names></name><xref rid="af1-cmh-2025-0166" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Diaz</surname><given-names initials="LA">Luis Antonio</given-names></name><xref rid="af2-cmh-2025-0166" ref-type="aff">
<sup>2</sup>
</xref><xref rid="af3-cmh-2025-0166" ref-type="aff">
<sup>3</sup>
</xref><xref rid="af4-cmh-2025-0166" ref-type="aff">
<sup>4</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Suparan</surname><given-names initials="K">Kanokphong</given-names></name><xref rid="af5-cmh-2025-0166" ref-type="aff">
<sup>5</sup>
</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0002-0871-9963</contrib-id><name name-style="western"><surname>Wijarnpreecha</surname><given-names initials="K">Karn</given-names></name><xref rid="c2-cmh-2025-0166" ref-type="corresp"/><xref rid="af6-cmh-2025-0166" ref-type="aff">
<sup>6</sup>
</xref><xref rid="af7-cmh-2025-0166" ref-type="aff">
<sup>7</sup>
</xref><xref rid="af8-cmh-2025-0166" ref-type="aff">
<sup>8</sup>
</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0002-8561-396X</contrib-id><name name-style="western"><surname>Arab</surname><given-names initials="JP">Juan Pablo</given-names></name><xref rid="c1-cmh-2025-0166" ref-type="corresp"/><xref rid="af4-cmh-2025-0166" ref-type="aff">
<sup>4</sup>
</xref><xref rid="af9-cmh-2025-0166" ref-type="aff">
<sup>9</sup>
</xref></contrib><aff id="af1-cmh-2025-0166">
<label>1</label>Department of Internal Medicine, Texas Tech University Health Sciences Center, Lubbock, TX, <country>USA</country></aff><aff id="af2-cmh-2025-0166">
<label>2</label>MASLD Research Center, Division of Gastroenterology and Hepatology, University of California San Diego, San Diego, CA, <country>USA</country></aff><aff id="af3-cmh-2025-0166">
<label>3</label>Departamento de Gastroenterolog&#237;a, Escuela de Medicina, Pontificia Universidad Cat&#243;licaCatolica de Chile, Santiago, <country>Chile</country></aff><aff id="af4-cmh-2025-0166">
<label>4</label>Observatorio Multic&#233;ntrico de Enfermedades Gastrointestinales, (OMEGA), Santiago, <country>Chile</country></aff><aff id="af5-cmh-2025-0166">
<label>5</label>Department of Microbiology, Faculty of Medicine, Chiang Mai University, Chiang Mai, <country>Thailand</country></aff><aff id="af6-cmh-2025-0166">
<label>6</label>Division of Gastroenterology and Hepatology, Department of Medicine, University of Arizona College of Medicine and Division of Gastroenterology and Hepatology, Phoenix, AZ, <country>USA</country></aff><aff id="af7-cmh-2025-0166">
<label>7</label>Department of Internal Medicine, Banner University Medical Center, Phoenix, AZ, <country>USA</country></aff><aff id="af8-cmh-2025-0166">
<label>8</label>BIO5 Institute, University of Arizona College of Medicine-Phoenix, Phoenix, AZ, <country>USA</country></aff><aff id="af9-cmh-2025-0166">
<label>9</label>Division of Gastroenterology, Hepatology, and Nutrition, Department of Internal Medicine, Virginia Commonwealth University School of Medicine, Richmond, VA, <country>USA</country></aff></contrib-group><author-notes><corresp id="c1-cmh-2025-0166">Corresponding author : Juan Pablo Arab Stravitz-Sanyal Institute of Liver Disease and Metabolic Health, Division of Gastroenterology, Hepatology, and Nutrition, Department of Internal Medicine, Virginia Commonwealth University School of Medicine, 1200 E. Broad St, 14th floor, PO Box 980341, Richmond, VA 23298, USA Tel: 804-827-0957, Fax: 804-827-0957, E-mail: <email>juanpablo.arab@vcuhealth.org</email></corresp><corresp id="c2-cmh-2025-0166">Karn Wijarnpreecha Division of gastroenterology and Hepatology, Department of Medicine, University of Arizona College of Medicine, Phoenix, Arizona 85004-2230, USA E-mail: <email>dr.karn.wi@gmail.com</email></corresp><fn><p>Editor: Han Ah Lee, Chung-Ang University College of Medicine, Korea</p></fn></author-notes><pub-date pub-type="ppub"><month>4</month><year>2025</year></pub-date><pub-date pub-type="epub"><day>17</day><month>2</month><year>2025</year></pub-date><volume>31</volume><issue>2</issue><issue-id pub-id-type="pmc-issue-id">487087</issue-id><fpage>e200</fpage><lpage>e202</lpage><history><date date-type="received"><day>11</day><month>2</month><year>2025</year></date><date date-type="accepted"><day>14</day><month>2</month><year>2025</year></date></history><pub-history><event event-type="pmc-release"><date><day>01</day><month>04</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>24</day><month>04</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-04-24 11:25:40.047"><day>24</day><month>04</month><year>2025</year></date></event></pub-history><permissions><copyright-statement>Copyright &#169; 2025 by The Korean Association for the Study of the Liver</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbynclicense">https://creativecommons.org/licenses/by-nc/3.0/</ali:license_ref><license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc/3.0/">http://creativecommons.org/licenses/by-nc/3.0/</ext-link>) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="cmh-2025-0166.pdf"/><related-article xmlns:xlink="http://www.w3.org/1999/xlink" related-article-type="letter" xml:lang="en" xlink:title="editorial" vol="31" page="654" journal-id="Clin Mol Hepatol" journal-id-type="nlm-ta" ext-link-type="pmc" xlink:href="PMC12016637"><article-title>Burden of alcohol use disorder, alcohol-related liver disease, and alcohol-related liver cancer: Editorial on &#8220;Global epidemiology of alcohol-related liver disease, liver cancer, and alcohol use disorder, 2000&#8211;2021</article-title><volume>31</volume><issue>2</issue><date><day>10</day><month>2</month><year>2025</year></date><fpage>654</fpage><lpage>657</lpage><source>Clinical and Molecular Hepatology</source><pub-id pub-id-type="pmcid">PMC12016637</pub-id><pub-id pub-id-type="pmid">39925000</pub-id></related-article><kwd-group><kwd>Alcohol</kwd><kwd>Alcohol-associated liver disease</kwd><kwd>Epidemiology</kwd><kwd>Gastrointestinal oncology</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta></custom-meta-group></article-meta></front><body><p>Dear Editor,</p><p>We sincerely appreciate the recent editorial highlighting our manuscript [<xref rid="b1-cmh-2025-0166" ref-type="bibr">1</xref>]. In our study, &#8220;Global Epidemiology of Alcohol-Related Liver Disease, Liver Cancer, and Alcohol Use Disorder, 2000&#8211;2021,&#8221; we examined the alcohol-related global, regional, and national epidemiological trends using the latest data from the GBD 2021 database. Our findings underscore the rising burden of alcohol-related liver disease (ALD), alcohol use disorder (AUD), and alcohol-attributable primary liver cancer in terms of incidence, prevalence, and mortality [<xref rid="b2-cmh-2025-0166" ref-type="bibr">2</xref>]. We also acknowledge the limitations pointed out by Wang et al., particularly concerning the underreporting of alcohol-related diseases, reliance on ICD-10 codes for diagnosing AUD, identifying comorbidities, and the inability to capture multiple liver diseases within the same patient, such as the overlap of metabolic dysfunction-associated and alcohol-associated liver disease (MetALD) [<xref rid="b3-cmh-2025-0166" ref-type="bibr">3</xref>,<xref rid="b4-cmh-2025-0166" ref-type="bibr">4</xref>].</p><p>Importantly, our study evaluated alcohol-attributable liver cancer based only on the primary diagnosis. However, alcohol can influence mortality in other forms of liver cancer and chronic liver disease, suggesting that our estimates are inherently conservative [<xref rid="b5-cmh-2025-0166" ref-type="bibr">5</xref>]. This is particularly concerning, given that ALD has an estimated prevalence nearly ten times lower than metabolic dysfunction-associated steatotic liver disease (MASLD). Yet, its liver-related complications&#8212;including liver disease progression&#8212;occur at a rate nearly ten times higher than MASLD alone [<xref rid="b6-cmh-2025-0166" ref-type="bibr">6</xref>]. In addition, a recent study has shown that alcohol may increase the risk of hepatocellular carcinoma in a dose-dependent fashion, being higher in patients with ALD [<xref rid="b7-cmh-2025-0166" ref-type="bibr">7</xref>]. These findings highlight ALD as the most aggressive phenotype within the steatotic liver disease spectrum and reinforce alcohol&#8217;s role as a significant disease modifier.</p><p>Beyond the increasing burden of ALD, the prevalence of metabolic comorbidities is also on the rise [<xref rid="b8-cmh-2025-0166" ref-type="bibr">8</xref>]. These risk factors act synergistically with alcohol to accelerate liver damage and promote carcinogenesis [<xref rid="b9-cmh-2025-0166" ref-type="bibr">9</xref>]. A recent position statement from 28 ALD experts [<xref rid="b3-cmh-2025-0166" ref-type="bibr">3</xref>], recommends obtaining detailed information on both recent and lifetime alcohol intake for assessing prognosis and defining management in individuals with metabolic dysfunction and steatotic liver disease. To enhance diagnostic accuracy, clinicians could also consider using alcohol biomarkers and validated questionnaires [<xref rid="b10-cmh-2025-0166" ref-type="bibr">10</xref>,<xref rid="b11-cmh-2025-0166" ref-type="bibr">11</xref>]. The presence of cardiometabolic risk factors should be evaluated within the context of alcohol consumption, as alcohol itself can contribute to other metabolic comorbidities [<xref rid="b3-cmh-2025-0166" ref-type="bibr">3</xref>]. Regular reassessment of both metabolic dysfunction and alcohol use over time is crucial, especially following changes in exposure to risk factors such as alcohol consumption or body weight. This is particularly relevant for individuals exceeding the weekly alcohol consumption thresholds. Addressing metabolic comorbidities through lifestyle modifications and pharmacological interventions remains a key strategy for reducing the overall burden of liver disease and cancer.</p><p>From a public health perspective, previous ecological studies have demonstrated that alcohol control policies are instrumental in reducing alcohol-related disease burden [<xref rid="b12-cmh-2025-0166" ref-type="bibr">12</xref>]. The World Health Organization (WHO) introduced the NCD Global Monitoring Framework, which aims for a 10% relative reduction in harmful alcohol consumption as part of its broader strategy to address behavioral risk factors [<xref rid="b13-cmh-2025-0166" ref-type="bibr">13</xref>]. In 2017, WHO identified a set of cost-effective and feasible interventions for noncommunicable disease prevention, known as the &#8220;Best Buys,&#8221; which were updated in 2023 to include 58 evidence-based interventions. Among the most effective strategies are increasing excise taxes on alcoholic beverages, enforcing comprehensive restrictions on alcohol advertising across all media platforms, and implementing strict controls on the physical availability of alcohol. WHO also developed the SAFER framework to facilitate the adoption and implementation of Best Buy policies, emphasizing the need for accessible screening, brief interventions, and treatment for alcohol-related disorders [<xref rid="b14-cmh-2025-0166" ref-type="bibr">14</xref>]. Thus, policies aimed at addressing alcohol and obesity could further contribute to reducing liver disease and primary liver cancer incidence and mortality [<xref rid="b15-cmh-2025-0166" ref-type="bibr">15</xref>].</p><p>The rising burden of ALD, compounded by the growing prevalence of metabolic comorbidities, underscores the urgent need for a dual-focus approach in both clinical and public health strategies. Comprehensive assessment of alcohol intake, alongside metabolic risk factors, is essential for optimizing patient management, while effective alcohol control policies, such as those outlined in WHO&#8217;s Best Buys and SAFER framework, play a pivotal role in curbing disease burden. By integrating targeted interventions at both individual and policy levels, we can mitigate liver disease progression and reduce the global impact of alcoholrelated and metabolic-driven carcinogenesis.</p></body><back><fn-group><fn fn-type="participating-researchers"><p>
<bold>Authors&#8217; contribution</bold>
</p><p>Writing, original draft &#8211; Pojsakorn Danpanichkul, Kanokphong Suparan. Writing, review, and editing &#8211; Karn Wijarnpreecha, Juan Pablo Arab, Luis Antonio Diaz.</p></fn><fn fn-type="COI-statement"><p>
<bold>Conflicts of Interest</bold>
</p><p>The authors have no conflicts to disclose.</p></fn></fn-group><glossary><title>Abbreviations</title><def-list><def-item><term>ALD</term><def><p>alcohol-related liver disease</p></def></def-item><def-item><term>AUD</term><def><p>alcohol use disorder</p></def></def-item><def-item><term>GBD</term><def><p>global burden of disease</p></def></def-item><def-item><term>ICD-10</term><def><p>international classification of diseases</p></def></def-item><def-item><term>MetALD</term><def><p>metabolic dysfunction-associated and alcohol-associated liver disease</p></def></def-item><def-item><term>WHO</term><def><p>World Health Organization</p></def></def-item></def-list></glossary><ref-list><title>REFERENCES</title><ref id="b1-cmh-2025-0166"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Oza</surname><given-names>N</given-names></name><name name-style="western"><surname>Leo</surname><given-names>J</given-names></name><name name-style="western"><surname>Choudhury</surname><given-names>A</given-names></name><name name-style="western"><surname>Huang</surname><given-names>DQ</given-names></name></person-group><article-title>Burden of alcohol use disorder, alcohol-related liver disease, and alcohol-related liver cancer: Editorial on &#8220;Global epidemiology of alcohol-related liver disease, liver cancer, and alcohol use disorder, 2000&#8211;2021</article-title><source>Clin Mol Hepatol</source><year>2025</year><volume>31</volume><fpage>654</fpage><lpage>657</lpage><pub-id pub-id-type="pmid">39925000</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3350/cmh.2025.0133</pub-id><pub-id pub-id-type="pmcid">PMC12016637</pub-id></element-citation></ref><ref id="b2-cmh-2025-0166"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Danpanichkul</surname><given-names>P</given-names></name><name name-style="western"><surname>D&#237;az</surname><given-names>LA</given-names></name><name name-style="western"><surname>Suparan</surname><given-names>K</given-names></name><name name-style="western"><surname>Tothanarungroj</surname><given-names>P</given-names></name><name name-style="western"><surname>Sirimangklanurak</surname><given-names>S</given-names></name><name name-style="western"><surname>Auttapracha</surname><given-names>T</given-names></name><etal/></person-group><article-title>Global epidemiology of alcohol-related liver disease, liver cancer, and alcohol use disorder, 2000&#8211;2021</article-title><source>Clin Mol Hepatol</source><year>2025</year><volume>31</volume><fpage>525</fpage><lpage>547</lpage><pub-id pub-id-type="pmid">39788109</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3350/cmh.2024.0835</pub-id><pub-id pub-id-type="pmcid">PMC12016609</pub-id></element-citation></ref><ref id="b3-cmh-2025-0166"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Arab</surname><given-names>JP</given-names></name><name name-style="western"><surname>D&#237;az</surname><given-names>LA</given-names></name><name name-style="western"><surname>Rehm</surname><given-names>J</given-names></name><name name-style="western"><surname>Im</surname><given-names>G</given-names></name><name name-style="western"><surname>Arrese</surname><given-names>M</given-names></name><name name-style="western"><surname>Kamath</surname><given-names>PS</given-names></name><etal/></person-group><article-title>Metabolic dysfunction and alcohol-related liver disease (MetALD): Position statement by an expert panel on alcohol-related liver disease</article-title><source>J Hepatol</source><year>2025</year><volume>82</volume><fpage>744</fpage><lpage>756</lpage><pub-id pub-id-type="pmid">39608457</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jhep.2024.11.028</pub-id></element-citation></ref><ref id="b4-cmh-2025-0166"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kim</surname><given-names>D</given-names></name><name name-style="western"><surname>Danpanichkul</surname><given-names>P</given-names></name><name name-style="western"><surname>Wijarnpreecha</surname><given-names>K</given-names></name><name name-style="western"><surname>Cholankeril</surname><given-names>G</given-names></name><name name-style="western"><surname>Loomba</surname><given-names>R</given-names></name><name name-style="western"><surname>Ahmed</surname><given-names>A</given-names></name></person-group><article-title>Current burden of steatotic liver disease and fibrosis among adults in the United States, 2017&#8211;2023</article-title><source>Clin Mol Hepatol</source><year>2025</year><volume>31</volume><fpage>382</fpage><lpage>393</lpage><pub-id pub-id-type="pmid">39610192</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3350/cmh.2024.0987</pub-id><pub-id pub-id-type="pmcid">PMC12016658</pub-id></element-citation></ref><ref id="b5-cmh-2025-0166"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Danpanichkul</surname><given-names>P</given-names></name><name name-style="western"><surname>Suparan</surname><given-names>K</given-names></name><name name-style="western"><surname>Pang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Auttapracha</surname><given-names>T</given-names></name><name name-style="western"><surname>Tham</surname><given-names>EKJ</given-names></name><name name-style="western"><surname>Srisurapanont</surname><given-names>K</given-names></name><etal/></person-group><article-title>Mortality of gastrointestinal cancers attributable to smoking, alcohol, and metabolic risk factors, and its association with socioeconomic development status 2000-2021</article-title><source>Am J Med</source><year>2025</year><month>Jan</month><day>6</day><comment>doi: 10.1016/j.amjmed.2024.12.019</comment><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.amjmed.2024.12.019</pub-id><pub-id pub-id-type="pmid">39778787</pub-id></element-citation></ref><ref id="b6-cmh-2025-0166"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Torp</surname><given-names>N</given-names></name><name name-style="western"><surname>Israelsen</surname><given-names>M</given-names></name><name name-style="western"><surname>Krag</surname><given-names>A</given-names></name></person-group><article-title>The steatotic liver disease burden paradox: unravelling the key role of alcohol</article-title><source>Nat Rev Gastroenterol Hepatol</source><year>2024</year><month>Dec</month><day>5</day><comment>doi: 10.1038/s41575-024-01022-y</comment><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41575-024-01022-y</pub-id><pub-id pub-id-type="pmid">39639157</pub-id></element-citation></ref><ref id="b7-cmh-2025-0166"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yun</surname><given-names>B</given-names></name><name name-style="western"><surname>Park</surname><given-names>H</given-names></name><name name-style="western"><surname>Ahn</surname><given-names>SH</given-names></name><name name-style="western"><surname>Oh</surname><given-names>J</given-names></name><name name-style="western"><surname>Kim</surname><given-names>BK</given-names></name><name name-style="western"><surname>Yoon</surname><given-names>JH</given-names></name></person-group><article-title>Liver cancer risk across metabolic dysfunction-associated steatotic liver disease and/or alcohol: A nationwide study</article-title><source>Am J Gastroenterol</source><year>2025</year><volume>120</volume><fpage>410</fpage><lpage>419</lpage><pub-id pub-id-type="pmid">38934496</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.14309/ajg.0000000000002920</pub-id></element-citation></ref><ref id="b8-cmh-2025-0166"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tan</surname><given-names>DJH</given-names></name><name name-style="western"><surname>Ng</surname><given-names>CH</given-names></name><name name-style="western"><surname>Muthiah</surname><given-names>M</given-names></name><name name-style="western"><surname>Yong</surname><given-names>JN</given-names></name><name name-style="western"><surname>Chee</surname><given-names>D</given-names></name><name name-style="western"><surname>Teng</surname><given-names>M</given-names></name><etal/></person-group><article-title>Rising global burden of cancer attributable to high BMI from 2010 to 2019</article-title><source>Metabolism</source><year>2024</year><volume>152</volume><fpage>155744</fpage><pub-id pub-id-type="pmid">38029839</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.metabol.2023.155744</pub-id><pub-id pub-id-type="pmcid">PMC11321712</pub-id></element-citation></ref><ref id="b9-cmh-2025-0166"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>D&#237;az</surname><given-names>LA</given-names></name><name name-style="western"><surname>Arab</surname><given-names>JP</given-names></name><name name-style="western"><surname>Louvet</surname><given-names>A</given-names></name><name name-style="western"><surname>Bataller</surname><given-names>R</given-names></name><name name-style="western"><surname>Arrese</surname><given-names>M</given-names></name></person-group><article-title>The intersection between alcohol-related liver disease and nonalcoholic fatty liver disease</article-title><source>Nat Rev Gastroenterol Hepatol</source><year>2023</year><volume>20</volume><fpage>764</fpage><lpage>783</lpage><pub-id pub-id-type="pmid">37582985</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41575-023-00822-y</pub-id></element-citation></ref><ref id="b10-cmh-2025-0166"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Arab</surname><given-names>JP</given-names></name><name name-style="western"><surname>Bataller</surname><given-names>R</given-names></name></person-group><article-title>Advancing alcohol-related liver disease: from novel biomarkers to refining selection for liver transplantation</article-title><source>Nat Rev Gastroenterol Hepatol</source><year>2023</year><volume>20</volume><fpage>71</fpage><lpage>72</lpage><pub-id pub-id-type="pmid">36474112</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41575-022-00723-6</pub-id></element-citation></ref><ref id="b11-cmh-2025-0166"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tavaglione</surname><given-names>F</given-names></name><name name-style="western"><surname>Amangurbanova</surname><given-names>M</given-names></name><name name-style="western"><surname>Yang</surname><given-names>AH</given-names></name><name name-style="western"><surname>Tincopa</surname><given-names>MA</given-names></name><name name-style="western"><surname>Ajmera</surname><given-names>V</given-names></name><name name-style="western"><surname>Richards</surname><given-names>L</given-names></name><etal/></person-group><article-title>Head-to-head comparison between phosphatidylethanol versus indirect alcohol biomarkers for diagnosis of MetALD versus MASLD: A prospective study</article-title><source>Aliment Pharmacol Ther</source><year>2025</year><volume>61</volume><fpage>1043</fpage><lpage>1054</lpage><pub-id pub-id-type="pmid">39825487</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/apt.18506</pub-id><pub-id pub-id-type="pmcid">PMC11870800</pub-id></element-citation></ref><ref id="b12-cmh-2025-0166"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>D&#237;az</surname><given-names>LA</given-names></name><name name-style="western"><surname>Idalsoaga</surname><given-names>F</given-names></name><name name-style="western"><surname>Fuentes-L&#243;pez</surname><given-names>E</given-names></name><name name-style="western"><surname>M&#225;rquez-Lomas</surname><given-names>A</given-names></name><name name-style="western"><surname>Ram&#237;rez</surname><given-names>CA</given-names></name><name name-style="western"><surname>Roblero</surname><given-names>JP</given-names></name><etal/></person-group><article-title>Impact of public health policies on alcohol-associated liver disease in Latin America: An ecological multinational study</article-title><source>Hepatology</source><year>2021</year><volume>74</volume><fpage>2478</fpage><lpage>2490</lpage><pub-id pub-id-type="pmid">34134172</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/hep.32016</pub-id></element-citation></ref><ref id="b13-cmh-2025-0166"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Probst</surname><given-names>C</given-names></name><name name-style="western"><surname>Manthey</surname><given-names>J</given-names></name><name name-style="western"><surname>Neufeld</surname><given-names>M</given-names></name><name name-style="western"><surname>Rehm</surname><given-names>J</given-names></name><name name-style="western"><surname>Breda</surname><given-names>J</given-names></name><name name-style="western"><surname>Rakovac</surname><given-names>I</given-names></name><etal/></person-group><article-title>Meeting the global NCD target of at least 10% relative reduction in the harmful use of alcohol: Is the WHO European region on track?</article-title><source>Int J Environ Res Public Health</source><year>2020</year><volume>17</volume><fpage>3423</fpage><pub-id pub-id-type="pmid">32423032</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/ijerph17103423</pub-id><pub-id pub-id-type="pmcid">PMC7277362</pub-id></element-citation></ref><ref id="b14-cmh-2025-0166"><label>14</label><element-citation publication-type="webpage"><comment>SAFER. SAFER - alcohol control initiative. WHO web site, &lt;<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.who.int/initiatives/SAFER" ext-link-type="uri">https://www.who.int/initiatives/SAFER</ext-link>&gt;. Accessed 6 Feb 2025</comment></element-citation></ref><ref id="b15-cmh-2025-0166"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>D&#237;az</surname><given-names>LA</given-names></name><name name-style="western"><surname>Fuentes-L&#243;pez</surname><given-names>E</given-names></name><name name-style="western"><surname>Idalsoaga</surname><given-names>F</given-names></name><name name-style="western"><surname>Ayares</surname><given-names>G</given-names></name><name name-style="western"><surname>Corsi</surname><given-names>O</given-names></name><name name-style="western"><surname>Arnold</surname><given-names>J</given-names></name><etal/></person-group><article-title>Association between public health policies on alcohol and worldwide cancer, liver disease and cardiovascular disease outcomes</article-title><source>J Hepatol</source><year>2024</year><volume>80</volume><fpage>409</fpage><lpage>418</lpage><pub-id pub-id-type="pmid">37992972</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jhep.2023.11.006</pub-id></element-citation></ref></ref-list></back></article></pmc-articleset>